Female Contraception - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Female Contraception - Pipeline Review, H1 2016

Female Contraception - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Female Contraception - Pipeline Review, H1 2016
Published Jun 15, 2016
73 pages — Published Jun 15, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Female Contraception - Pipeline Review, H1 2016, provides an overview of the Female Contraception pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Female Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Female Contraception
- The report reviews pipeline therapeutics for Female Contraception by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Female Contraception therapeutics and enlists all their major and minor projects
- The report assesses Female Contraception therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Female Contraception

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Female Contraception
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Female Contraception pipeline

  
Source:
Document ID
GMDHC8180IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Female Contraception Overview81
Therapeutics Development92
  Pipeline Products for Female Contraception Overview91
  Pipeline Products for Female Contraception Comparative Analysis101
Female Contraception Therapeutics under Development by Companies111
Female Contraception Therapeutics under Investigation by Universities/Institutes121
Female Contraception Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Female Contraception Products under Development by Companies161
Female Contraception Products under Investigation by Universities/Institutes171
Female Contraception Companies Involved in Therapeutics Development185
  Agile Therapeutics, Inc.181
  ANI Pharmaceuticals, Inc.191
  Evofem, Inc.201
  Mithra Pharmaceuticals S.A.211
  Orbis Biosciences, Inc.221
Female Contraception Therapeutics Assessment2310
  Assessment by Monotherapy Products231
  Assessment by Combination Products241
  Assessment by Target252
  Assessment by Mechanism of Action272
  Assessment by Route of Administration292
  Assessment by Molecule Type312
Drug Profiles3327
  (drospirenone + estetrol) Drug Profile332
  (estradiol acetate + nestorone) Drug Profile352
  (estradiol acetate + prasterone + progesterone) Drug Profile372
  AG-200 ER Drug Profile391
  AG-200 SP Drug Profile401
  AG-20015 Drug Profile414
  Amphora Drug Profile452
  etonogestrel ER Drug Profile471
  EVE-106 Drug Profile481
  levonorgestrel Drug Profile492
  LJ-102 Drug Profile511
  Monoclonal Antibody Conjugates for Contraception Drug Profile521
  NOV-1003 Drug Profile531
  S-003296 Drug Profile541
  S-0101255 Drug Profile551
  Small Molecule 1 for Fertility Control Drug Profile561
  Small Molecule 2 for Fertility Control Drug Profile571
  Small Molecule to Modulate Progesterone Receptor for Fertility Control Drug Profile581
  Synthetic Peptides for Contraception Drug Profile591
Female Contraception Dormant Projects602
Female Contraception Discontinued Products621
Female Contraception Product Development Milestones639
  Featured News &Press Releases631
    Apr 05, 2016: FDA Feedback On Spa Estelle: A New Step Closer To The Launch Of Estelle Phase III Pivotal Clinical Studies631
    Apr 01, 2016: Topline Results Of Food Effect Study Of The Product Candidate Estelle, The New Combined Oral Contraceptive Composed Of 15 mg Of Estetrol (E4) And 3 mg Of Drospirenone631
    Mar 24, 2016: Already 4 European Countries Fully Approved Protocol Of MIT-ES001-C301 Estelle Phase III Clinical Study641
    Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial641
    Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial651
    Sep 22, 2015: Evofem Announces FDA Acceptance of New Drug Application for Amphora as a Contraceptive651
    Aug 31, 2015: Agile Therapeutics Announces Completion of Patient Recruitment in Twirla Phase 3 SECURE Clinical Trial661
    Aug 26, 2015: The European Journal Of Contraception And Reproductive Health Care Publishes Two Scientific Articles About E4 (Estetrol) Dinox Phase II Study: Two Of The Most Read Papers By The Scientific Community671
    Jul 13, 2015: Aquila Solutions,Partners with Evofem to Submit New Drug Application to U.S. FDA for Amphora as a Contraceptive681
    Jul 06, 2015: Evofem Submits New Drug Application to U.S. FDA for Amphora as a Contraceptive681
    Jan 13, 2015: Evofem Announces Pre-NDA Meeting With FDA for Amphora691
    Dec 01, 2014: Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch691
    Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study691
    Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla701
    Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion702
Appendix722
  Methodology721
  Coverage721
  Secondary Research721
  Primary Research721
  Expert Panel Validation721
  Contact Us721
  Disclaimer731

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Female Contraception - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Female-Contraception-Pipeline-Review-H1-2016-2088-15948>
  
APA:
Global Markets Direct - Market Research. (2016). Female Contraception - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Female-Contraception-Pipeline-Review-H1-2016-2088-15948>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.